CEP55 Antibody [H23H21]

Catalog No.: F3504

    Application: Reactivity:
    • Lane 1: LNCAP, Lane 2: HT-1080, Lane 3: T-47D, Lane 4: MCF7
    1/

    当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:200
    Application
    WB, IP
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human, Mouse, Rat
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    55 kDa
    ポジティブコントロール LNCaP cell; HT-1080 cell; SK-MEL-28 cell; MDA-MB-231 cell; T-47D cell; MCF7 cell; MCF7 cell (treated with Doxorubicin 0.5 μM, 24 hr); MCF7 cell (treated UV 100 mJ, 6 hr recovery)
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/Tris-Triton Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/Tris-Triton Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/Tris-Triton Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.

    Datasheet & SDS

    生物学的記述

    Specificity

    CEP55 Antibody [H23H21] recognizes endogenous levels of total CEP55 protein.

    タンパク質の局在
    細胞質、細胞骨格
    Uniprot ID
    Q53EZ4
    Clone
    H23H21
    Synonym(s)
    Centrosomal protein of 55 kDa; Cep55; Up-regulated in colon cancer 6; CEP55; C10orf3
    Background
    CEP55 (Centrosomal Protein 55) is a multifunctional, centrosome-associated, α-helical coiled-coil protein that plays a pivotal role in cytokinesis, specifically facilitating the final abscission step by recruiting and interacting with crucial proteins such as ALIX and TSG101 at the midbody during late mitosis. It localizes to the mitotic spindle and subsequently to the spindle midzone and midbody, ensuring the proper separation of daughter cells and the completion of cell division. CEP55 directly regulates the PI3K/AKT signaling pathway by binding to the catalytic subunit of PI3K, thereby promoting AKT activation and enhancing cell survival, proliferation, and resistance to apoptosis. CEP55 also influences stemness and cell fate through its involvement in the management of midbody remnants, which can affect stem cell properties and tumorigenicity. Additionally, CEP55 is required for proper ciliogenesis, as its loss leads to defects in cilia formation. Overexpression of CEP55 is linked to tumor progression, enhanced cell migration and invasion, and chemotherapy resistance, primarily driven by activation of the PI3K/AKT pathway and disruption of critical cell cycle regulators such as p21, ultimately resulting in chromosomal instability and poorer prognosis across multiple cancer types.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください